In this article:
Key Points
-
Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back.
-
Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine.
-
Both companies have increased their dividends at a…